Zentiva and Mabxience have announced that they have partnered to launch the Alymsys (bevacizumab) biosimilar rival to Avastin that Mabxience developed in alliance with Stada.
Mabxience Allies With Zentiva For European Bevacizumab Launch
Avastin Rival Alymsys Launched Shortly After Partner Stada Introduced Oyavas
Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.
